Author:
Miceli M H,Dong L,Grazziutti M L,Fassas A,Thertulien R,Van Rhee F,Barlogie B,Anaissie E J
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference46 articles.
1. Gahrton G . Progress in hematopoietic stem cell transplantation in multiple myeloma. Curr Opin Hematol 2005; 12: 463–470.
2. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Effect of adding thalidomide to the treatment of multiple myeloma with tandem autotransplants. N Engl J Med 2006 (in press).
3. Anaissie E, Jacobson J, Fassas A, Zangari M, Thertulien R, van Rhee F et al. Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: a study of 475 consecutive patients. In: 45th American Society of Hematology Annual Meeting 2003; 6 December 2003; San Diego, 2003.
4. Perez-Simon JA, Martin A, Caballero D, Corral M, Nieto MJ, Gonzalez M et al. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 1279–1283.
5. Fujii K, Aoyama M, Shinagawa K, Matsuo K, Takenaka K, Ikeda K et al. Risk of neutropenic fever and early infectious complications after autologous peripheral blood stem cell transplantation for malignant diseases. Int J Hematol 2002; 76: 186–191.
Cited by
102 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献